Claims for Patent: 9,120,873

Summary for Patent: 9,120,873

Title:	Recombinantly produced human factor VIII and IX
Abstract:	A recombinant human factor VIII or IX protein having a human glycosylation pattern but the protein is devoid of N-glycolylneuraminic acid and/or the carbohydrate group Gal.alpha.-3Gal.
Inventor(s):	Sandberg; Helena (Bromma, SE), Stenlund; Peter (Bromma, SE), Schroder; Carola (Neuried, DE), Casademunt; Elisabeth (Munchen, DE), Tiemeyer; Maya (Munchen, DE)
Assignee:	Octapharma AG (Lachen, CH)
Application Number:	12/737,815
Patent Claims:	1. A recombinant protein having a human-like glycosylation pattern but devoid of all N-glycolylneuraminic acid and carbohydrate group Gal.alpha.-3Gal, wherein the recombinant protein is human factor VIII. 2. The recombinant protein of claim 1, wherein the factor VIII is a deletion modification of native factor VIII partially or entirely the B-domain of native factor VIII. 3. The recombinant protein according to claim 2 further comprising, in place of the partially or entirely lacking B-domain, a linker peptide having 10-25 amino acid residues. 4. The recombinant protein according claim 3 wherein the linker peptide has 14-20 amino acid residues. 5. The recombinant protein according to claim 1 having a higher affinity to von Willebrand factor than recombinant factor VIII produced in a non-human mammalian cell. 6. The recombinant protein of claim 5, wherein the mammalian cell is a murine cell. 7. The recombinant protein according to claim 1 having a higher binding capacity to von Willebrand factor than recombinant factor VIII produced in a non-human mammalian cell. 8. The recombinant protein of claim 7, wherein the mammalian cell is a murine cell. 9. The recombinant protein according to claim 2 having a higher affinity to von Willebrand factor than recombinant factor VIII produced in a non-human mammalian cell. 10. The recombinant protein according to claim 3 having a higher binding capacity to von Willebrand factor than recombinant factor VIII produced in a non-human mammalian cell. 11. The recombinant protein according to claim 1 produced in a human cell line. 12. The recombinant protein of claim 11, wherein the human cell line is an immortalized cell line selected from the group consisting of kidney, bladder, liver, lung, cardiac muscle, smooth muscle, ovary, retina, nerve, and gastrointestinal cell lines. 13. The recombinant protein according to claim 11, wherein the human cell line is a human embryonic kidney cell line (HEK). 14. The recombinant protein of claim 13, wherein the HEK is selected from the group consisting of HEK 293 (ATCC CRL-1573, DSM ACC 305, ECACC 85120602) and HEK 293F (Invitrogen R79007). 15. A pharmaceutical composition comprising the recombinant protein according to claim 1 and a pharmaceutically acceptable excipient. 16. A complex comprising the recombinant protein according to claim 1 and von Willebrand factor. 17. A pharmaceutical composition comprising the recombinant protein according to claim 2, and a pharmaceutically acceptable excipient. 18. A complex comprising the recombinant protein according to claim 2 and von Willebrand factor.

Details for Patent 9,120,873

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Baxalta Us Inc.	VONVENDI	von willebrand factor (recombinant)	For Injection	125577	12/08/2015		2028-08-21